Determination of Blood Everolimus Concentrations in Kidney and Liver Transplant Recipients Using the Sirolimus Antibody Conjugated Magnetic Immunoassay (ACMIA)
Bouzas, L.; Carlos, J. Tutor
Clinical Laboratory 57(5-6): 403-406
2011
ISSN/ISBN: 1433-6510 PMID: 21755832 Document Number: 11980
Background: The aim of our study was to evaluate the possible determination of everolimus concentrations using the newly-introduced sirolimus antibody conjugated magnetic immunoassay (ACMIA). Methods: Everolimus concentrations were determined in 100 blood samples from kidney (n = 47) and liver (n = 53) transplant recipients using the IMx® sirolimus microparticle enzyme immunoassay (MEIA) from Abbott as previously described (Clin Biochem 2007;40:132-36) and sirolimus ACMIA from Siemens Healthcare Diagnostics Ltd. Results: The ACMIA everolimus values were significantly higher than those of MEIA (p Conclusions: The sirolimus ACMIA on the Dimension® platform, which does not require manual pre-treatment of the blood samples, may be an acceptable option for therapeutic everolimus monitoring, significantly reducing technician time in comparison to other widely-used immunoassays.
Document emailed within 1 workday
